このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Lunit マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Beomseok Brandon Suh

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

更新なし

Recent updates

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Apr 19

CEO（最高経営責任者

Beomseok Brandon Suh

no data

在職期間

Mr. Beomseok Brandon Suh is Chief Executive Officer of Lunit Inc. He studied medicine in Seoul National University College of Medicine and is a board certified physician in Family Medicine, trained at Seou...

Lunit マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Recent updates

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Inc. announced that it expects to receive KRW 171.5 billion in funding from a group of investors

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit Announces Publication of New Study Featuring Lunit SCOPE IO

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

New minor risk - Shareholder dilution

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America

Third quarter 2023 earnings released: ₩948 loss per share (vs ₩1,576 loss in 3Q 2022)

Lunit Inc. Receives U.S. Food and Drug Administration (FDA) 510(K) Clearance for its 3D Breast Tomosynthesis (DBT) Ai Solution, Lunit Insight DBT

Lunit Inc. has completed a Follow-on Equity Offering in the amount of KRW 200.20077 billion.

Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes

New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023

Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Lunit Inc. Provides Revenue Guidance for the Second Half of the Year 2022

CEO（最高経営責任者

在職期間

Lunit マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Recent updates

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Inc. announced that it expects to receive KRW 171.5 billion in funding from a group of investors

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit Announces Publication of New Study Featuring Lunit SCOPE IO

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

New minor risk - Shareholder dilution

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America

Third quarter 2023 earnings released: ₩948 loss per share (vs ₩1,576 loss in 3Q 2022)

Lunit Inc. Receives U.S. Food and Drug Administration (FDA) 510(K) Clearance for its 3D Breast Tomosynthesis (DBT) Ai Solution, Lunit Insight DBT

Lunit Inc. has completed a Follow-on Equity Offering in the amount of KRW 200.20077 billion.

Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes

New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023

Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Lunit Inc. Provides Revenue Guidance for the Second Half of the Year 2022

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04